Subsequent trials such as the Colchicine Cardiovascular Outcomes Trial (COLCOT) and the LoDoCo2 trial (9–12) have further confirmed the involvement of specific inflammatory pathways in human ASCVD and emphasized the NOD, LRR, and NLRP3 inflammasome-related pathways as effective therapeutic targets for alleviating ASCVD. Here, NLRP3 is linked to atherosclerosis.